HC Wainwright Estimates Scholar Rock FY2030 Earnings

Scholar Rock Holding Corporation (NASDAQ:SRRK) – Equities researchers at HC Wainwright issued their FY2030 earnings estimates for shares of Scholar Rock in a report issued on Monday, January 26th. HC Wainwright analyst A. Maldonado forecasts that the company will earn $1.07 per share for the year. HC Wainwright has a “Buy” rating and a $58.00 price objective on the stock. The consensus estimate for Scholar Rock’s current full-year earnings is ($2.42) per share.

Scholar Rock (NASDAQ:SRRK) last posted its earnings results on Friday, November 14th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.02). During the same quarter in the previous year, the firm earned ($0.66) EPS.

Several other research analysts have also issued reports on SRRK. Cantor Fitzgerald reiterated an “overweight” rating on shares of Scholar Rock in a research report on Thursday, December 11th. JPMorgan Chase & Co. upped their price objective on shares of Scholar Rock from $46.00 to $47.00 and gave the company an “overweight” rating in a research note on Tuesday, November 18th. Wolfe Research began coverage on shares of Scholar Rock in a research report on Tuesday, November 18th. They issued an “outperform” rating and a $42.00 target price on the stock. Citigroup began coverage on Scholar Rock in a research note on Friday, January 9th. They set a “buy” rating and a $55.00 price objective on the stock. Finally, Barclays raised their price target on Scholar Rock from $45.00 to $52.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 17th. Four analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $51.14.

Scholar Rock Stock Down 2.0%

SRRK stock opened at $43.99 on Tuesday. The firm has a 50-day moving average price of $43.98 and a 200-day moving average price of $37.42. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.41. Scholar Rock has a 12 month low of $22.71 and a 12 month high of $48.28. The stock has a market capitalization of $4.49 billion, a P/E ratio of -13.97 and a beta of 0.63.

Institutional Investors Weigh In On Scholar Rock

A number of large investors have recently modified their holdings of SRRK. Wellington Management Group LLP grew its stake in shares of Scholar Rock by 124.5% in the third quarter. Wellington Management Group LLP now owns 4,545,887 shares of the company’s stock worth $169,289,000 after purchasing an additional 2,521,022 shares in the last quarter. Holocene Advisors LP purchased a new position in Scholar Rock during the 3rd quarter worth approximately $91,670,000. Norges Bank purchased a new stake in shares of Scholar Rock in the second quarter valued at $41,628,000. Balyasny Asset Management L.P. acquired a new stake in shares of Scholar Rock in the second quarter worth $33,062,000. Finally, UBS Group AG grew its holdings in shares of Scholar Rock by 233.8% during the third quarter. UBS Group AG now owns 1,131,787 shares of the company’s stock valued at $42,148,000 after buying an additional 792,760 shares in the last quarter. Institutional investors and hedge funds own 91.08% of the company’s stock.

Insider Buying and Selling

In other news, insider Mo Qatanani sold 136,462 shares of the business’s stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $45.21, for a total transaction of $6,169,447.02. Following the completion of the sale, the insider directly owned 108,964 shares of the company’s stock, valued at $4,926,262.44. The trade was a 55.60% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Vikas Sinha sold 16,755 shares of the company’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $42.70, for a total value of $715,438.50. Following the sale, the chief financial officer owned 583,245 shares of the company’s stock, valued at $24,904,561.50. This represents a 2.79% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 305,687 shares of company stock valued at $13,540,573. Company insiders own 13.30% of the company’s stock.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).